Optic Nerve Disorders Treatment Market

The global optic nerve disorders treatment market was worth US$ 8.5 billion in 2019 and is expected to grow at a CAGR of 4.8% through 2030. In several cases, essential manifestations of optic neuritis incorporate photophobia, decreased night vision, and eye redness.

Grown-up optic neuritis and pediatric optic neuritis are two categories based on age group of patients determined to have optic neuritis. The optic nerve comprises of axons emerging from retina and communicating visual data to visual cores. Irritation of this optic nerve causes ill-advised working and can prompt vision misfortune due to demolition of myelin sheath connected to optic nerve. 40% to 50% patients with different sclerosis (MS) create optic neuritis and around 30% optic neuritis patients show indications of numerous sclerosis.

An ongoing article distributed in the Journal of Neurology expressed that the yearly frequency of optic neuritis in the U.S. is discovered to associate with 5/1,000,000, with assessed pervasiveness 115/1,000,000. Developing mindfulness about early detection of optic neuritis related with different sclerosis and accessibility of moderate treatment alternatives are relied upon to drive the worldwide optic neuritis treatment market during the gauge time frame.

Expansion in geriatric populace, ascend in various sclerosis tolerant pool, developing mindfulness and reasonable costs are the central point pushing the market. Symptoms of optic neuritis treatment medications and development of the conventional medications market are probably going to limit the worldwide optic nerve disorder treatment market during the gauge time frame. Accessibility of repayment and entrenched medical care foundation are different elements expected to enlarge the market during the estimate time frame.

North America is anticipated to hold largest market share over the forecast period. The region held highest market share in 2019. Some of the factors fueling the regional growth include growing awareness among the population regarding optical neuritis and MS, rising aging population, and well-established healthcare infrastructure in North America. Moreover, Europe is expected to witness remarkable growth and expected to be the second largest revenue contributor in global market.

Optic Nerve Disorders Treatment Market Value Share Analysis, by Geography (2022)

The report titled “Optic Nerve Disorders Treatment Market- Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global optic nerve disorders treatment market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.

The global optic nerve disorders treatment market is segmented on the basis of treatment type, indication, end-user, and geography. Based on treatment type, the global market can be segmented into Pharmacological Treatment and surgery. The Pharmacological Treatment segment can be further sub segmented into Combination Drugs, Prostaglandins, Corticosteroids, Beta Interferons, Carbonic Anhydrase Inhibitors, Alpha-adrenergic Agonists, Beta Blockers, and Others. By indication, the global market can be segmented into Optic Neuritis, Glaucoma, Congenital Optic Atrophy, Optic Neuropathy, and Others. The Optic Neuropathy segment can be further sub segmented into Non-arteritic Ischemic Optic Neuropathy and Arteritic Ischemic Optic Neuropathy. The end-user segment can be divided into Hospitals, Clinics, Ambulatory Surgery Centers, and Others. Based on geography, the global optic nerve disorders treatment market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

North America is sub-segmented into the United States, Canada and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Belgium, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, the UAE, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.

The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on optic nerve disorders treatment. Further, market share of prominent companies in the global optic nerve disorders treatment market would also be estimated.

The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the optic nerve disorders treatment companies.

The global optic nerve disorders treatment market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the optic nerve disorders treatment business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global optic nerve disorders treatment market.

Some of the prominent player involved in global optic nerve disorders treatment market include Allergan plc., Mallinckrodt Pharmaceuticals, Novartis AG, Santen Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Aerie Pharmaceuticals, Inc. and Bionure Farma, S.L.

Segmentation:

By Treatment Type:

• Pharmacological Treatment
  • Combination Drugs
  • Prostaglandins
  • Corticosteroids
  • Beta Interferons
  • Carbonic Anhydrase Inhibitors
  • Alpha-adrenergic Agonists
  • Beta Blockers
  • Others
• Surgery

By Indication:

• Optic Neuritis
• Glaucoma
• Congenital Optic Atrophy
• Optic Neuropathy
  • Non-arteritic Ischemic Optic Neuropathy
  • Arteritic Ischemic Optic Neuropathy
• Others

By End-User:

• Hospitals
• Clinics
• Ambulatory Surgery Centers
• Others

By Geography :

• North America
  • United States
  • Canada
  • Rest of North America
• Europe
  • Germany
  • United Kingdom
  • Belgium
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • India
  • China
  • Australia
  • Rest of Asia Pacific
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Rest of Middle East & Africa
• South America
  • Brazil
  • Rest of South America